BioRestorative Therapies BRTX Stock
BioRestorative Therapies Price Chart
BioRestorative Therapies BRTX Financial and Trading Overview
| BioRestorative Therapies stock price | 0.38 USD |
| Previous Close | 0.41 USD |
| Open | 0.4 USD |
| Bid | 0.29 USD x 200 |
| Ask | 0.51 USD x 200 |
| Day's Range | 0.39 - 0.43 USD |
| 52 Week Range | 0.16 - 1.89 USD |
| Volume | 646.85K USD |
| Avg. Volume | 10.97M USD |
| Market Cap | 10.42M USD |
| Beta (5Y Monthly) | 0.605 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.06 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
BRTX Valuation Measures
| Enterprise Value | 6.86M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7865385 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 29.118319 |
| Price/Book (mrq) | 3.4369748 |
| Enterprise Value/Revenue | 19.161 |
| Enterprise Value/EBITDA | -0.489 |
Trading Information
BioRestorative Therapies Stock Price History
| Beta (5Y Monthly) | 0.605 |
| 52-Week Change | -76.065% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 1.89 USD |
| 52 Week Low | 0.16 USD |
| 50-Day Moving Average | 0.29 USD |
| 200-Day Moving Average | 0.84 USD |
BRTX Share Statistics
| Avg. Volume (3 month) | 10.97M USD |
| Avg. Daily Volume (10-Days) | 806.48K USD |
| Shares Outstanding | 25.48M |
| Float | 24.18M |
| Short Ratio | 0.24 |
| % Held by Insiders | 12.12% |
| % Held by Institutions | 7.26% |
| Shares Short | 6.59M |
| Short % of Float | 26.25% |
| Short % of Shares Outstanding | 25.85% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -14612.57% |
| Gross Margin | 92.08% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -118.80% |
| Return on Equity (ttm) | -241.13% |
Income Statement
| Revenue (ttm) | 357.87K USD |
| Revenue Per Share (ttm) | 0.03 USD |
| Quarterly Revenue Growth (yoy) | -7.29% |
| Gross Profit (ttm) | 329.55K USD |
| EBITDA | -14014733 USD |
| Net Income Avi to Common (ttm) | -11056581 USD |
| Diluted EPS (ttm) | -1.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.59M USD |
| Total Cash Per Share (mrq) | 0.14 USD |
| Total Debt (mrq) | 28.77K USD |
| Total Debt/Equity (mrq) | 0.95 USD |
| Current Ratio (mrq) | 2.353 |
| Book Value Per Share (mrq) | 0.119 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11817969 USD |
| Levered Free Cash Flow (ttm) | -9714683 USD |
Profile of BioRestorative Therapies
| Country | United States |
| State | NY |
| City | Melville |
| Address | 40 Marcus Drive |
| ZIP | 11747 |
| Phone | 631 760 8100 |
| Website | https://www.biorestorative.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Q&A For BioRestorative Therapies Stock
What is a current BRTX stock price?
BioRestorative Therapies BRTX stock price today per share is 0.38 USD.
How to purchase BioRestorative Therapies stock?
You can buy BRTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioRestorative Therapies?
The stock symbol or ticker of BioRestorative Therapies is BRTX.
Which industry does the BioRestorative Therapies company belong to?
The BioRestorative Therapies industry is Biotechnology.
How many shares does BioRestorative Therapies have in circulation?
The max supply of BioRestorative Therapies shares is 25.48M.
What is BioRestorative Therapies Price to Earnings Ratio (PE Ratio)?
BioRestorative Therapies PE Ratio is now.
What was BioRestorative Therapies earnings per share over the trailing 12 months (TTM)?
BioRestorative Therapies EPS is -1.06 USD over the trailing 12 months.
Which sector does the BioRestorative Therapies company belong to?
The BioRestorative Therapies sector is Healthcare.
BioRestorative Therapies BRTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
- {{ link.label }} {{link}}